Damon Colbert
Division of Corporate Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549

March 4, 2010

RE:  CytoGenix, Inc.
     2008 Form 10-K filed May 15, 2009
     Form 10-Q for Qrt. Ended 3/31/2009 filed May 20, 2009 File No. 000-26807


Dear Mr. Colbert:


We have the  restated  Annual  10-K for 2008 and the 10-Q for March 31,  2009 as
redlined  documents  for your  review,  to take  into  account  establishing  an
impairment  provision against the December 31, 2008 inventory and to revise them
based on your comments in your December 17, 2009 letter to the Company.

We have not received the consent of LBB & Associates  LTD, LLP to include  their
audit  report dated April 4, 2008  relating to the  December 31, 2007  financial
statements.  As I noted in my January 14,  2010 letter to you,  there is a money
issue with them created by prior  management and based on the Company's  current
situation of not having any financial  resources,  we see a potential problem in
getting  their  consent.  I have noted this fact in our letter  addressing  your
comments.

The Company does not have the thousands of dollars that will be required to file
the redlined correspondence responses to your comment letter(s) and then a final
live  version.  I can email  the  comment  letter  and  redlined  correspondence
versions  to you if you  will  provide  me with an  email  address,  then we can
address the live version at the time that it is ready to go.

Respectfully,


/s/ Randy Moseley
-----------------
Randy Moseley
Chief Financial Officer
817-296-3877
rmoseley@hotmail.com